American Journal of PharmTech Research

The increasing prevalence of metabolic disorders, gastrointestinal diseases, immune dysregulation, and lifestyle-related illnesses has intensified global interest in preventive nutrition and gut microbiome research. Ayurveda, the traditional system of Indian medicine, emphasizes the concepts of Agni (digestive and metabolic fire) and Ahara Vidhi (dietary rules and eating practices) as the foundation of health and disease prevention. Classical Ayurvedic texts describe Agni as the central factor governing digestion, absorption, assimilation, tissue nourishment, immunity, and longevity. Disturbance of Agni leads to the formation of Ama (metabolic toxins), which is considered the root cause of many diseases. Similarly, Ahara Vidhi outlines systematic principles regarding food quality, quantity, combinations, timing, environment, and eating behaviour to maintain physiological balance. Recent advances in gut microbiome science reveal that dietary habits profoundly influence microbial diversity, intestinal permeability, immune modulation, metabolic homeostasis, and neuro-gastrointestinal interactions. Emerging evidence suggests significant conceptual parallels between Ayurvedic understanding of gut health and modern microbiota centered nutrition. Practices such as mindful eating, individualized diet planning, seasonal dietary adaptation, and proper food combinations demonstrate potential relevance in maintaining microbial balance and preventing chronic inflammatory disorders. This review aims to critically explore the correlation between Ayurvedic principles of Agni and Ahara Vidhi with current concepts of gut microbiome science and preventive nutrition. The article highlights the integrative potential of Ayurveda in developing personalized, sustainable, and preventive dietary strategies for modern healthcare systems.

Type 2 diabetes mellitus (T2DM) frequently coexists with hypertension, substantially increasing the risk of cardiovascular morbidity, mortality, and progressive renal disease. Contemporary management of these comorbid conditions relies heavily on polypharmacy, with oral antidiabetic drugs and antihypertensive agents prescribed concomitantly for prolonged durations. Among antidiabetic therapies, the fixed-dose combination of glimepiride and metformin remains widely used because it addresses both insulin resistance and impaired insulin secretion. Angiotensin receptor blockers (ARBs) are commonly recommended antihypertensive agents in patients with T2DM due to their established renoprotective and cardioprotective benefits. However, accumulating experimental and clinical evidence suggests that ARBs are not metabolically inert; instead, they may influence glucose homeostasis, insulin sensitivity, and the pharmacokinetic disposition of antidiabetic drugs. These effects raise clinically relevant concerns regarding potential pharmacokinetic and pharmacodynamic interactions when ARBs are co-administered with glimepiride-metformin combinations. Preclinical investigations have demonstrated enhanced hypoglycemic responses when certain ARBs, such as losartan and telmisartan, are combined with glimepiride-metformin, possibly due to synergistic pharmacodynamic actions or alterations in drug metabolism and transport. Telmisartan, in particular, exhibits partial peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist activity, which may confer additional insulin-sensitizing effects. Clinical evidence, however, remains limited and inconsistent, with some studies suggesting modest improvements in glycemic control and others indicating an increased risk of hypoglycemia, especially in regimens containing sulfonylureas. Moreover, most available studies lack integrated pharmacokinetic-pharmacodynamic assessments and fail to reflect chronic real-world combination therapy. This review critically synthesizes current preclinical and clinical evidence on pharmacokinetic and pharmacodynamic interactions between glimepiride-metformin combinations and ARBs. It highlights existing knowledge gaps, underscores the clinical necessity for systematic and ARB specific evaluation, and proposes future research directions aimed at optimizing safety and therapeutic outcomes in patients with coexisting T2DM and hypertension.

Among the drugs used in long-term cardiovascular management, carvedilol occupies a special position owing to its combined non-selective beta-blockade and alpha-1 receptor antagonism. However, turning this pharmacological advantage into consistent clinical benefit is not straightforward. The molecule belongs to BCS Class II, meaning it crosses biological membranes readily but barely dissolves in physiological fluids. On top of that, extensive hepatic extraction during the first pass through the liver trims oral bioavailability to somewhere between 25 and 35 percent, and an elimination half-life of only 6 to 10 hours forces patients to take the drug multiple times a day. Together, these characteristics create the conditions for erratic plasma concentrations, missed doses, and avoidable side effects. Encapsulating carvedilol within polymer-matrix microspheres is a strategy with growing experimental support: the polymer network acts as a physical throttle on drug escape, stretching the release window well beyond what any immediate-release tablet can offer. This article brings together evidence published between 2016 and 2025 on how microsphere formulations of carvedilol are built, what polymers are chosen and why, how the finished particles are tested, and what the most informative recent studies have found. Across this body of work, entrapment efficiencies consistently exceed 75 percent when formulation conditions are properly optimised, and release profiles extending to 12 hours or beyond are regularly achieved. Floating, pH-sensitive, and mucoadhesive variants each address specific absorption or tolerability concerns, broadening the design toolbox available to formulators.